TAT and acute respiratory distress syndrome: SN50 treatment not only down-regualted TF and PAI-1 expressions in pulmonary tissue, but also inhibited secretions of TF, PAI-1 and TAT and decreased pulmonary collagen III level, and promoted APC production in BALF, demonstrating that SN50 effectively corrected hypercoagulation and fibrinolysis inhibition in LPS-induced ARDS.